XML 56 R40.htm IDEA: XBRL DOCUMENT v3.24.0.1
Goodwill and Intangible Assets (Tables)
 12 Months Ended
Dec. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of acquired intangible assets
Components of the Company’s acquired intangible assets are comprised of the following:
December 31, 2023December 31, 2022
GrossAccumulated amortization and impairment chargesNetGrossAccumulated amortization and impairment chargesNet
Utrophin program acquired(1)
$— $— $— $4,015 $(4,015)$— 
Discuva platform acquired(2)
13,583 (13,583)— 12,900 (12,900)— 
Option over non-financial asset859 (859)— 816 (816)— 
Other intangibles140 (140)— 133 (133)— 
$14,582 $(14,582)$— $17,864 $(17,864)$— 

(1) During the year ended December 31, 2023, the Company dissolved the wholly-owned subsidiary, Muox Limited, a dormant entity. The Utrophin program intangible assets, which arose from the Muox Limited acquisition were fully impaired and have been removed from the Company’s accounting records.
(2) In conjunction with the significant change in the Company’s strategy and shift in focus to the therapeutic area of oncology, the Company determined that it would cease further investment in the Discuva Platform. Management concluded that the carrying amount of the acquired Discuva Platform intangible asset may not be recoverable and performed an assessment to calculate the fair value of the asset using a probability-weighted approach which was compared to the carrying value of the asset. An impairment charge of $8,468 which represented the carrying value of the Discuva Platform was recognized during the year ended December 31, 2022. This impairment charge is presented as impairment of intangible assets in the consolidated statements of operations and comprehensive loss.